Skip to search formSkip to main contentSkip to account menu

Nucleoside Analog DFP-10917

Known as: DFP-10917 
A deoxycytosine analog with potential antineoplastic activity. Upon administration, DFP-10917 is phosphorylated to generate its nucleotide form that… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

2'-cyano-2'-deoxyarabinofuranosylcytosine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase 1/2 study of DFP‐10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia
DFP‐10917, a deoxycytidine nucleoside analogue, has a unique mechanism of action resulting in leukemic cell death when… 
2019
2019
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules
SummaryPurpose DFP-10917 is a novel deoxycytidine analog with a unique mechanism of action. Brief exposure to high concentrations… 
2018
2018
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofranocyl-cytosine (DFP-10917, CNDAC) is a 2'-deoxycytidine analog with antitumor activity… 
2018
2018
Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer
SummaryBackground DFP-10917 is a cytotoxic deoxycytidine analogue that causes DNA fragmentation, G2/M–phase arrest, and apoptosis… 
2017
2017
What are the latest advancements in acute myeloid leukemia therapy?
7000 (2016). 8 Lancet JE, Hoering A, Uy GL et al. Survival following allogeneic hematopoietic cell transplantation in older high… 
2017
2017
Novel Development of Chemotherapy for Relapsed and Refractory AML Based on the Promising Functional Mechanism of Cytidine Analog, DFP-10917
2016
2016
Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study
Background: DFP-10917 is a nucleoside analog similar to cytarabine with a unique mechanism of action when administered at a low… 
2015
2015
Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia
Background: DFP-10917 is a nucleoside analog similar to cytarabine with a unique mechanism of action upon prolonged… 
2015
2015
First report of a phase I/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia.
7077 Background: DFP-10917 has a unique mechanism of action upon prolonged administration at a low dose. Under such… 
2015
2015
Abstract 2551: Brca1-deficient ovarian cancer cells are sensitized to the DNA-strand-breaking nucleoside analog sapacitabine that synergizes with PARP inhibition
Sapacitabine is an orally bioavailable prodrug of the deoxycytidine analog, CNDAC. Sapacitabine is currently in a Phase III… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)